Live price temporarily unavailable.
Qiagen (QGEN) is a Health Care company in the Russell 1000. Latest news and coverage below.
Qiagen revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.34B | $1.42B | $1.50B | $1.53B | $1.87B | $2.25B | $2.14B | $1.97B | $1.98B | $2.09B |
| Growth (year over year) | +4.5% | +5.9% | +5.9% | +1.6% | +22.5% | +20.4% | −4.9% | −8.2% | +0.7% | +5.7% |
| Gross profit | $844.7M | $922.6M | $1.00B | $1.01B | $1.23B | $1.45B | $1.38B | $1.23B | $967.4M | $1.30B |
| Gross margin | 63.1% | 65.1% | 66.6% | 65.9% | 65.9% | 64.4% | 64.7% | 62.8% | 48.9% | 62.2% |
| Operating income | $98.8M | $153.4M | $266.6M | −$26.1M | $386.4M | $630.1M | $531.5M | $409.9M | $97.7M | $465.9M |
| Operating margin | 7.4% | 10.8% | 17.8% | −1.7% | 20.7% | 28.0% | 24.8% | 20.9% | 4.9% | 22.3% |
| Net income | $80.4M | $40.4M | $190.4M | −$41.5M | $359.2M | $512.6M | $423.2M | $341.3M | $83.6M | $424.9M |
| Net margin | 6.0% | 2.8% | 12.7% | −2.7% | 19.2% | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
| EPS (diluted) | $0.34 | $0.17 | $0.82 | −$0.18 | $1.53 | $2.21 | $1.84 | $1.48 | $0.37 | $1.94 |
| Balance sheet | ||||||||||
| Cash and equivalents | $439.2M | $657.7M | $1.16B | $623.6M | $598.0M | $880.5M | $730.7M | $668.1M | $663.6M | $839.0M |
| Total assets | $4.31B | $5.04B | $5.75B | $5.24B | $5.87B | $6.15B | $6.29B | $6.12B | $5.69B | $6.28B |
| Total liabilities | $1.70B | $2.50B | $3.11B | $2.70B | $3.07B | $3.05B | $2.82B | $2.31B | $2.12B | $2.50B |
| Long-term debt | $1.07B | $1.76B | $1.67B | $1.42B | $1.88B | $1.09B | $1.47B | $921.8M | $839.7M | $1.65B |
| Shareholders' equity | $2.61B | $2.54B | $2.63B | $2.54B | $2.80B | $3.10B | $3.47B | $3.81B | $3.57B | $3.78B |
| Cash flow | ||||||||||
| Operating cash flow | $341.6M | $286.8M | $359.5M | $330.8M | $457.8M | $639.0M | $715.3M | $459.5M | $673.6M | $654.3M |
| Capital expenditure | $74.5M | $90.1M | $109.8M | $118.0M | $132.8M | $189.9M | $129.2M | $149.7M | $167.2M | $201.0M |
| Free cash flow | $267.1M | $196.7M | $249.7M | $212.9M | $325.0M | $449.1M | $586.0M | $309.7M | $506.4M | $453.3M |
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $54.2M |
| Share buybacks | $0 | $61.0M | $104.7M | $74.5M | $64.0M | $100.0M | $0 | $0 | $292.1M | $280.1M |
From Qiagen's 20-F filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
About Qiagen
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer (CEO).
- Headquarters
- Pl Venlo, Netherlands From SEC filings, Oct 2026
Recent News
No recent news mentioning Qiagen in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International